Arcutis Biotherapeutics Inc (ARQT)

Arcutis reported its first profitable quarter in Q3 2025, driven by increasing demand and the launch of ZORYVE foam 0.3%. The company launched ZORYVE cream 0.05% for atopic dermatitis in children aged 2 to 5 following FDA approval in early October 2025. Arcutis and Kowa Pharmaceuticals terminated their promotion agreement for ZORYVE, with Arcutis assuming responsibilities. Positive Phase 2 results were announced for ZORYVE cream 0.05% in infants with atopic dermatitis. ARQT stock has trended up by 77.86% over the last six months, with analysts issuing "Buy" ratings and raising price targets.

Arcutis Biotherapeutics experiences some demand seasonality for its products, with the first quarter seeing fluctuations in gross-to-net revenue due to deductible resets and changes in insurance plans. Gross-to-net rates tend to quickly return to a steady state in subsequent quarters, and overall demand for ZORYVE continues to grow. The company also observes a "portfolio effect," where increased prescribing across the ZORYVE portfolio leads to more consistent and efficient prescription processing.

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing topical treatments for immune-mediated dermatological diseases, operating within the Healthcare sector, specifically in the Biotechnology industry. The company's core business revolves around its lead asset, ZORYVE (roflumilast), a highly selective phosphodiesterase-4 (PDE4) inhibitor, available as a steroid-free topical cream and foam. Major products and pipeline candidates include ZORYVE cream 0.3% approved for plaque psoriasis, ZORYVE cream 0.15% indicated for mild to moderate atopic dermatitis, ZORYVE cream 0.05% approved for atopic dermatitis in pediatric patients 2 to 5 years of age, ZORYVE foam 0.3% (ARQ-154) approved for scalp and body psoriasis and seborrheic dermatitis, ARQ-255 (development halted), ARQ-252 in development for chronic hand eczema and vitiligo, and ARQ-234 in development for atopic dermatitis.

Arcutis Biotherapeutics is headquartered in Westlake Village, California, and focuses its commercialization efforts for its approved products, particularly the ZORYVE franchise, on the United States market.

Arcutis Biotherapeutics has cultivated a positive brand reputation through its commitment to addressing unmet needs in immune-mediated dermatological diseases and the strong performance of its ZORYVE franchise. The company is recognized for championing meaningful innovation in medical dermatology, with ZORYVE expanding its leadership as a top branded non-steroidal topical. The company's products are valued by clinicians for their efficacy, safety, rapid onset, and ease of use. The termination of the co-promotion agreement with Kowa Pharmaceuticals is not expected to negatively impact 2026 net product sales guidance.

Institutional investors hold a dominant and highly concentrated position in Arcutis Biotherapeutics, with 406 institutional owners and shareholders holding a total of 133,816,887 shares. Major institutional shareholders include Rubric Capital Management LP, Suvretta Capital Management, LLC, Frazier Life Sciences Management, L.P., BlackRock, Inc., Vanguard Group Inc, Jennison Associates LLC, Polar Capital Holdings Plc, State Street Corp, Gilder Gagnon Howe & Co Llc, and Morgan Stanley.